Saturday, 10 October 2026European Markets

INTEROIL EXPL PROD Stock Was 11.54% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with INTEROIL EXPL PROD (IOX.OL) jumping 11.54% to kr3.12 on Monday, after three sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.06% to kr1,450.21, after three successive sessions in a row of gains, on what was a somewhat up trend trading session today.

INTEROIL EXPL PROD's last close was kr2.80, 74.59% under its 52-week high of kr11.00.

About INTEROIL EXPL PROD

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company in Argentina and Colombia. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-1.66.

More news about INTEROIL EXPL PROD (IOX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com